Growth Hormone Research Market

CJC-1295

A GHRH analog commonly discussed in growth-hormone optimization circles and research-market peptide stacks.

GHRHGrowth HormoneSecretagogue

Also referenced as: Drug Affinity Complex CJC-1295

Also appears in: Muscle Growth

Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Category
Growth Hormone

Primary lane: Growth Hormone. Also surfaces under Muscle Growth for browsing and discovery.

Aliases
1

Drug Affinity Complex CJC-1295

Signal depth
Low

No FDA label signal · 1 trials · 32 PubMed results

Promising
Research evidence

CJC-1295 has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

CJC-1295 has 1 name-matched clinical trial (highest phase: Phase 2) and 32 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.

Human data
Phase 2
Trial quality
Randomized
Outcomes
Surrogate / early
Replication
Multiple papers
Literature
Established
PHASE2 · Randomized A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity The Journal of Clinical Endocrinology & Metabolism · 40 citations Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults Substance Use & Misuse · 39 citations Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions Endocrinology · 38 citations Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog Journal Article The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Journal Article Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What CJC-1295 is

CJC-1295 is a synthetic analog of growth hormone-releasing hormone. It is often discussed in research-market contexts as a way to stimulate endogenous growth-hormone signaling rather than supplying growth hormone directly.

Why it matters

It sits near the center of the “GH secretagogue” conversation, especially when paired in discussion with compounds like ipamorelin. That makes it a useful profile for understanding the difference between growth-hormone pathway signaling and actual FDA-approved hormone medicines.

Regulatory context

CJC-1295 is not FDA-approved as a peptide medicine in the United States. Most discussion around it belongs to the research-market or performance-oriented side of the peptide world.

Practical reading note

This is one of the clearest examples of a peptide that gets discussed as if it were a routine wellness therapy even though its real regulatory footing is much looser.